Prosecution Insights
Last updated: November 20, 2026

Sarah Cooper Patterson, USPTO Patent Examiner

Listed by the USPTO as PATTERSON, SARAH COOPER

Tech Center 1600 • Art Units: 1600 1675

This examiner grants 56% of resolved cases

Analysis

PATTERSON, SARAH COOPER has resolved 43 cases, with an allowance rate of 55.8% and a median of 1492 days to allowance. The interview lift is 53.6%, so interview activity has a substantial association with allowance results in this record.

The profile includes The Regents of the University of California, University of Massachusetts, and The Regents of the University of Michigan among the recorded companies. Listed firms include Casimir Jones, S.C., WILSON SONSINI GOODRICH & ROSATI, and BOZICEVIC, FIELD & FRANCIS LLP. The 1492-day median supports early attention to prosecution timing.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

55.8%
Allow Rate
-4.2% vs TC avg
107
Total Applications
+53.6%
Interview Lift
1492
Avg Prosecution Days
Based on 43 resolved cases, 2023–2026

Rejection Statute Breakdown

3.1%
§101 Eligibility
11.6%
§102 Novelty
27.0%
§103 Obviousness
37.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17630321 DETECTION OF MEDIATORS OF DOPAMINE TRANSMISSION Final Rejection UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
17639525 METHODS OF TREATING KRAS MUTANT CANCERS Non-Final OA The Regents of the University of California
17762980 COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES Non-Final OA The Regents of the University of Michigan
18302630 METHOD OF CREATING HUMAN PLURIPOTENT STEM CELL DERIVED BRAIN PERICYTE-LIKE CELLS Final Rejection Wisconsin Alumni Research Foundation
17776524 TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS Non-Final OA University of Virginia Patent Foundation
17587465 MOLECULE SPECIFICALLY ACTING IN A TISSUE WHERE A CELL DEATH IS BEING OBSERVED Final Rejection Chugai Seiyaku Kabushiki Kaisha
17617165 RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNE SIGNALING STATES IN MYELOID MALIGNANCIES VIA THE UBIQUITIN CONJUGATING ENZYME UBE2N Non-Final OA CHILDREN'S HOSPITAL MEDICAL CENTER
17909658 COMBINED USE OF CTB006 AND PONATINIB Final Rejection Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Sarah Cooper Patterson's allowance rate?

55.8% of resolved applications examined by Sarah Cooper Patterson were allowed (43 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.

Does an interview help with examiner Sarah Cooper Patterson?

This examiner's interview lift is +53.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Sarah Cooper Patterson take to allow a patent?

Applications allowed by Sarah Cooper Patterson took 1,492 days on average from filing to allowance.

Which art unit does examiner Sarah Cooper Patterson work in?

Sarah Cooper Patterson examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month